Nicolas Trebouta - Onxeo SA Executive
| C4X Stock | EUR 0.11 0.01 8.33% |
Executive
Dr. Nicolas Trebouta has served as Member of the Board Permanent Representative of Financiere de la Montagne at Bioalliance Pharma SA as of June 29, 2011. Since 2004, he was via his company Financiere de la Montagne, investing in biotechnology companies, directly or through funds. He cofounded Chevrillon et Associe in 2000 and through this structure achieved several LBO such as Picard, CPI or Alingia . He was a Medical Doctor and shareholder of BioAlliance Pharma SA since 2008. Dr. Trebouta also serves as Manager of SARL Financiere de la Montagne, SCI Fleurus Immobilier and SCI du Trillon Chairman of SAS Dragon 8, and Director of GIE IO, among others. since 2011.
| Tenure | 13 years |
| Phone | 33 1 45 58 76 00 |
| Web | https://www.onxeo.com |
Onxeo SA Management Efficiency
The company has return on total asset (ROA) of (0.1108) % which means that it has lost $0.1108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3966) %, meaning that it generated substantial loss on money invested by shareholders. Onxeo SA's management efficiency ratios could be used to measure how well Onxeo SA manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 9.91 M in total debt with debt to equity ratio (D/E) of 0.31, which is about average as compared to similar companies. Onxeo SA has a current ratio of 3.77, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Onxeo SA until it has trouble settling it off, either with new capital or with free cash flow. So, Onxeo SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Onxeo SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Onxeo to invest in growth at high rates of return. When we think about Onxeo SA's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jo Shuttleworth | Gamma Communications plc | N/A | |
| James Bushell | Gamma Communications plc | N/A | |
| CFP CFP | Reinsurance Group of | N/A | |
| Keely Westbury | Gamma Communications plc | N/A | |
| Siobhan Carr | Gamma Communications plc | N/A | |
| Justin Coombes | Gamma Communications plc | N/A | |
| Oksana Lukasheva | The Hanover Insurance | N/A | |
| KinShun Cheng | Reinsurance Group of | 49 | |
| Haleem Gul | Gamma Communications plc | N/A | |
| Andrew Smethurst | Gamma Communications plc | N/A | |
| Samantha Russell | Gamma Communications plc | N/A | |
| Danny Jacobs | Gamma Communications plc | N/A | |
| Helen Higgons | Gamma Communications plc | N/A | |
| Matt Davies | Gamma Communications plc | N/A | |
| Leslie Barbi | Reinsurance Group of | 56 | |
| Steve Holden | Gamma Communications plc | N/A | |
| Tony MacKenzie | Gamma Communications plc | N/A | |
| Raymond Kleeman | Reinsurance Group of | N/A | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 |
Onxeo SA Leadership Team
Elected by the shareholders, the Onxeo SA's board of directors comprises two types of representatives: Onxeo SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onxeo. The board's role is to monitor Onxeo SA's management team and ensure that shareholders' interests are well served. Onxeo SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onxeo SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elisabeth Carstensen, Director of Alliance Management, Member of the Executive Committee | ||
| Russell Greig, Independent Member of the Board | ||
| Michel Forest, Vice President Quality Qualified Person and Member of the Executive Committee | ||
| Caroline Lemarchand, Preclinical R&D Director, Member of the Executive Committee | ||
| Huiping Jiang, VP Assurance | ||
| Sonia Vallons, Quality Assurance Director, Member of the Executive Committee | ||
| Thomas Hofstaetter, Independent Member of the Board | ||
| MD MPH, CEO Pres | ||
| Delphine Lucas, Regulatory Affairs Director, Member of the Executive Committee | ||
| Francoise Bono, Chief Scientific Officer, Member of the Executive Committee | ||
| Nicolas Trebouta, Member of the Board - Permanent Representative of Financiere de la Montagne | ||
| Audrey LegentilDumery, Director of Human Resources, Member of the Executive Committee | ||
| Judith Greciet, Chief Executive Officer, Member of the Executive Committee, Member of the Board | ||
| Nicolas Fellman, Vice President, Chief Financial Officer, Member of the Executive Committee | ||
| David Solomon, Independent Member of the Board | ||
| Louis Kayitalire, Vice President Head of Research & Development | ||
| Remi Droller, Member of the Board - Representative of Kurma Life Science Partners | ||
| Daniele GuyotCaparros, Independent Member of the Board | ||
| Olivier Beaumont, Chief Medical Officer, Member of the Executive Committee | ||
| Aude Michel, Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | ||
| Patrick Langlois, Independent Chairman of the Board | ||
| Graham Dixon, Chief Scientific Officer, Head of Research & Development, Member of the Executive Committee | ||
| Joseph Zakrzewski, Non-Executive Chairman of the Board | ||
| Philippe Maitre, Executive Vice President and Chief of U.S. Operations | ||
| Nicolas Fellmann, CFO Director |
Onxeo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onxeo SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 111.06 M | |||
| Shares Owned By Insiders | 13.25 % | |||
| Shares Owned By Institutions | 12.72 % | |||
| Price To Earning | 50.90 X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 5.35 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Onxeo SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Onxeo SA's short interest history, or implied volatility extrapolated from Onxeo SA options trading.
Pair Trading with Onxeo SA
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onxeo SA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onxeo SA will appreciate offsetting losses from the drop in the long position's value.Moving against Onxeo Stock
| 0.44 | SVM | Sovereign Metals | PairCorr |
| 0.44 | DBPE | Xtrackers LevDAX | PairCorr |
The ability to find closely correlated positions to Onxeo SA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onxeo SA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onxeo SA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onxeo SA to buy it.
The correlation of Onxeo SA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onxeo SA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onxeo SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onxeo SA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Onxeo SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Onxeo Stock analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |